Source: Rheumatology. Unidade: FM
Subjects: DOENÇAS AUTOIMUNES, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SHINJO, Samuel Katsuyuki et al. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, v. 61, n. 8, p. 3351-3361, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab773. Acesso em: 17 out. 2024.APA
Shinjo, S. K., Souza, F. H. C. de, Borges, I. B. P., Santos, A. M. D., Miossi, R., Misse, R. G., et al. (2022). Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, 61( 8), 3351-3361. doi:10.1093/rheumatology/keab773NLM
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2024 out. 17 ] Available from: https://doi.org/10.1093/rheumatology/keab773Vancouver
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2024 out. 17 ] Available from: https://doi.org/10.1093/rheumatology/keab773